<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Anti-epidermal growth factor receptor (EGFR) antibodies, cetuximab, and panitumumab are established as a new treatment option for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>Among activating mutations downstream of EGFR, the KRAS mutation, which is present in 30-45 % of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, has shown to be a predictive biomarker of resistance to anti-EGFR antibody therapy based on Caucasian studies </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Forty-three chemotherapy-refractory Japanese patients with mCRC were treated with cetuximab monotherapy or cetuximab plus irinotecan </plain></SENT>
<SENT sid="3" pm="."><plain>KRAS, BRAF, and PIK3CA mutational status of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was assessed </plain></SENT>
<SENT sid="4" pm="."><plain>The association between mutational status and treatment outcome was evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of 43 tumors, KRAS, BRAF, and PIK3CA mutations were identified in 12 (27.9 %), 2 (4.7 %), and 2 (4.7 %) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS subgroup showed better clinical outcomes than the mutant KRAS subgroup in terms of response rate (RR) (31.3 % vs. 0 %, P = 0.034) and progression-free survival (PFS) (5.1 vs. 3.0 months, P = 0.017) </plain></SENT>
<SENT sid="7" pm="."><plain>No responder to treatment was shown in 16 (37.2 %) patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> harboring mutations in any one of the three genes (KRAS, BRAF, and PIK3CA) </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:mp ids='MP_0002169'>wild-type</z:mp> subgroup without any mutations in KRAS, BRAF, and PIK3CA had a better RR (37.0 %) and PFS (6.4 months) than did the <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS subgroup </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Our data indicated that KRAS status is predictive of cetuximab response in the Japanese population </plain></SENT>
<SENT sid="10" pm="."><plain>The additional analysis of BRAF and PIK3CA genes in <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS patients could improve selection of patients who are most likely to benefit from anti-EGFR antibody therapy </plain></SENT>
</text></document>